Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	58.59	137.33	108.97	110.62	333.56	171.16
Short-Term Investments	125.49	116.59	231.74	114.45	102.95	118.96
Cash & Short-Term Investments	184.08	253.92	340.71	225.07	436.51	290.12
Cash Growth	-38.69%	-25.47%	51.38%	-48.44%	50.46%	65.01%
Accounts Receivable	48.26	27.68	11.34	3.35	1.86	-
Receivables	48.26	27.68	11.34	3.35	1.86	-
Inventory	85.21	45.58	18.33	10.15	5.88	-
Prepaid Expenses	9.94	11.15	4.36	7.54	5.76	6.49
Restricted Cash	0.47	0.55	-	-	-	-
Other Current Assets	1.74	-	-	-	-	-
Total Current Assets	329.69	338.87	374.73	246.12	450	296.6
Property, Plant & Equipment	76.99	90.21	59.42	69	47.13	41.29
Goodwill	-	-	77.18	146.96	146.96	-
Other Intangible Assets	7.63	9.81	35.34	55.33	71.34	-
Long-Term Accounts Receivable	-	-	-	-	0.08	-
Other Long-Term Assets	47.25	39.57	35.24	13.75	4.7	2.4
Total Assets	461.56	478.45	581.9	531.16	720.22	340.29

Liabilities

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Accounts Payable	12.34	13.81	4.55	10.6	12.66	8.01
Accrued Expenses	32.8	52.91	59.36	37.66	29.67	17.43
Current Portion of Long-Term Debt	10.15	2.5	-	-	-	-
Current Portion of Leases	17.21	8.35	4.91	4.75	4.44	3.47
Current Unearned Revenue	6.33	10.74	6.87	9.36	7.85	7.91
Other Current Liabilities	1.22	0.92	-	4.92	6.35	4.16
Total Current Liabilities	80.05	89.22	75.68	67.29	60.96	40.98
Long-Term Debt	421.04	426.6	379.37	280.64	180.53	-
Long-Term Leases	35.04	40.99	34.18	39.13	27.15	25.87
Long-Term Unearned Revenue	85.55	70.42	78.58	74.15	77.29	47.95
Other Long-Term Liabilities	2.91	2.84	1.49	1.49	-	-
Total Liabilities	624.59	630.06	569.3	462.69	345.93	114.8

Shareholders' Equity

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Common Stock	0.11	0.09	0.08	0.07	0.07	0.05
Additional Paid-In Capital	2,044	1,927	1,767	1,466	1,501	1,070
Retained Earnings	-2,207	-2,078	-1,754	-1,398	-1,126	-844.2
Comprehensive Income & Other	0.07	0.01	-0.37	-0.02	-	0
Total Common Equity	-163.03	-151.6	12.6	68.47	374.29	225.49
Shareholders' Equity	-163.03	-151.6	12.6	68.47	374.29	225.49
Total Liabilities & Equity	461.56	478.45	581.9	531.16	720.22	340.29

Additional Metrics

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Total Debt	483.45	478.43	418.47	324.51	212.11	29.34
Net Cash (Debt)	-299.37	-224.52	-77.76	-99.44	224.4	260.78
Net Cash Growth	-	-	-	-	-13.95%	48.33%
Net Cash Per Share	-3.09	-2.65	-1.07	-1.47	3.87	6.00
Filing Date Shares Outstanding	104.9	88.21	82.8	71.45	71.38	56.93
Total Common Shares Outstanding	104.9	87.96	82.39	71.58	69.18	52.37
Working Capital	249.64	249.64	299.05	178.83	389.04	255.62
Book Value Per Share	-1.55	-1.72	0.15	0.96	5.41	4.31
Tangible Book Value	-170.66	-161.41	-99.92	-133.83	155.98	225.49
Tangible Book Value Per Share	-1.63	-1.84	-1.21	-1.87	2.25	4.31
Machinery	-	-	-	25.73	23.12	21.82
Construction In Progress	-	-	-	3.11	1.54	2.39
Leasehold Improvements	-	-	-	7.48	5.97	5.37

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2024

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jan 1, 2000

Data Sources Report a data error